Abstract:for BSC were consistent in the validation MAICs for both OS and PFS. CONCLUSIONS: Based on ITCs, evidence suggests nivolumab demonstrates greater overall survival compared to regorafenib, cabozantinib and BSC. Limitations of indirect comparisons without common comparators are acknowledged. As this analysis did not consider comparisons on safety, these findings should be confirmed with real-world evidence evaluating both effectiveness and safety outcomes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.